INTRODUCTION
Human adenovirus (hAd)-based vectors have been extensively investigated since the early 1980s, for gene therapy and vaccination applications. hAds can induce strong humoral and cell-mediated immunity without integration into the host genome, which make them attractive vaccine candidates with respect to both efficacy and safety (Tatsis & Ertl, 2004) . Nevertheless, widespread immunity against the most commonly used hAd serotypes in humans, as well as the risk of complementation with wild-type viruses, may limit their utility for human as well as veterinary vaccination. These difficulties may be overcome by using non-human adenoviruses, several of which are now under investigation (Bangari & Mittal, 2006) . Canine adenoviruses (CAVs) belong to the genus Mastadenovirus, family Adenoviridae (Davison et al., 2003) . Two serotypes of CAV have been described in dogs, CAV-1 and CAV-2. CAV-1 is responsible for infectious canine hepatitis, whereas CAV-2 generally leads only to mild infection of the upper respiratory tract. A very effective live vaccine based on serotype 2 is in routine use worldwide for the vaccination of dogs against both serotypes, and has an excellent safety record. Vectors derived from CAV-2 are able to transfer large transgenes into a wide variety of cells, even those of human origin, as efficiently as hAds (Klonjkowski et al., 1997; Kremer et al., 2000) . Recently, several different CAV-2-based vectors have been evaluated for the purpose of gene therapy (Hemminki et al., 2003; Keriel et al., 2006; Kremer et al., 2000; Soudais et al., 2001 ) and vaccination (Fischer et al., 2002; Liu et al., 2008; Yang et al., 2008; Zhang et al., 2008) .
Vector design requires extensive characterization of viral gene expression. In replication-competent vectors, the transgene and associated regulatory elements must be inserted in order to preserve the integrity of viral sequences associated with essential functions. Such vectors have typically been derived by replacement of the non-essential early 3 (E3) region, defined as the region surrounded by pVIII and fiber genes, with the expression cassette. Recently, we have described a new type of replicative CAV-2 vector harbouring an insertion between the left inverted terminal repeat (ITR) and E1 region (Tordo et al., 2008) . However, even replication-defective vectors that have deletions or modifications in essential genes, such as the E1 region (Klonjkowski et al., 1997; Kremer et al., 2000) , require precise genetic engineering. Indeed, production of such vectors requires that all of the missing essential gene products are provided in trans by a complementary cell line. The development of E1-and E3-deleted CAV-2 vectors has been underpinned by characterization of the corresponding transcriptional units (Fischer et al., 2002; Shibata et al., 1989; Tsukiyama et al., 1988) . Further efficient modification involving other regions of the CAV-2 genome will require characterization of the remaining CAV-2 transcriptional units.
Detailed information about gene expression during the CAV-2 life cycle is not available currently. It is known that hAd gene expression is temporally controlled, giving rise to a biphasic viral cycle. To initiate replication of the adenovirus genome, a group of transcriptional units, E1-E4, are expressed as early as 1 h post-infection, whereas expression of the genes encoding structural proteins begins at a later stage, along with the onset of viral DNA replication. The adenovirus late mRNAs are processed from a single RNA precursor whose synthesis is under the control of the major late promoter (MLP). All late transcripts possess a typical polyadenylation (polyA) tract at their 39 extremity and are grouped into several families based on their site of polyadenylation. At their 59 end, viral late mRNAs contain an untranslated region termed the tripartite leader sequence (TPL), which is required for preferential translation of viral proteins at the late stage of infection. The MLP and TPL thus have a major impact on transcription and translation during the late stage of infection. Regarding the late coding sequences of CAV-2, only the gene encoding the fiber protein has been cloned and sequenced (Rasmussen et al., 1995) , while the major late open reading frames (ORFs) and transcribed regions have only been inferred by sequence analysis.
There is considerable interest in modifying late genes in order to design retargeted vectors with a modified hexon (Vigant et al., 2008) or penton (Schagen et al., 2008) base. To provide a basis for further development of CAV-2 vectors, we have therefore analysed the transcriptional organization of the major late transcriptional unit (MLTU) of the Manhattan strain of CAV-2. We have identified and characterized the major late transcripts, from splicing acceptor site to polyA sites. Moreover, the MLP and TPL sequences of CAV-2 were identified and functionally characterized.
METHODS
Cells and viruses. Dog kidney (DK) cells (ECACC 93120836) were grown as monolayers in Dulbecco's modified Eagle's medium supplemented with 10 % fetal calf serum (Gibco-BRL) at 37 uC in 5 % CO 2 . The Manhattan strain of CAV-2 (Appel et al., 1973) was propagated in DK cells and purified by double banding on CsCl gradient. Purified vectors were titrated by end-point dilution and titres were expressed as TCID 50 ml 21 .
Construction of CAV-2 cDNA libraries. DK cells were plated in 6 cm diameter culture dishes. Twenty-four hours later, the cells were washed with PBS, infected with CAV-2 at 1 TCID 50 per cell in 1 ml medium and maintained at 37 uC in 5 % CO 2 with regular agitation for 1 h. The cells were rinsed twice and then cultured in complete medium. At 2, 6, 12, 16 and 24 h after infection, total RNA was extracted by using the Qiagen RNeasy Mini kit. Polyadenylated RNAs were purified from total RNA by using the NucleoTrap mRNA kit (Macherey-Nagel). Libraries were generated using the SMART RACE cDNA Amplification kit (Clontech), which created cDNAs with adaptor sequences appended at both 59 and 39 ends.
Rapid amplification of cDNA ends (RACE). RACE was carried out by using Phusion High-Fidelity DNA polymerase (Finnzymes) using one primer that hybridized to the adaptor extensions introduced at the 59 or 39 end of cDNAs and a second gene-specific primer (Supplementary Table S1 , available in JGV Online). The purified amplification products were cloned into the pCR2.1 vector (Invitrogen) and sequenced. Sequences were analysed using VectorNTI software (Invitrogen).
Production of plasmids expressing luciferase. pCMV-luc (L0) was constructed by introducing the luciferase gene downstream of the CMV promoter of the pCI plasmid (Promega). The whole TPL sequence or portions thereof were then amplified with Phusion DNA polymerase from the cDNA sequence of the hexon gene. These elements were inserted upstream of luc in L0 by using the restriction sites NheI and MluI, thereby producing different constructs as follows: pCMV-leaders1/2/3-luc (L123), pCMV-leaders1/2-luc (L12), pCMV-leaders2/3-luc (L23) and pCMV-leader3-luc (L3). The putative MLP sequence, along with the first leader fragment and the first intron between leader fragments 1 and 2, was amplified by using Phusion DNA polymerase and inserted into the BglII and NheI restriction sites of L23, to replace the CMV promoter and the chimeric intron, thereby creating the pMLP-L construct. A minimal promoter sequence was amplified without the leader sequences and inserted into L0 by using the BglII and PstI restriction sites of L0, replacing only the CMV promoter.
Analysis of luciferase activity. The plasmids expressing luciferase were used to transfect DK cells by using the calcium-phosphate method. The cells were lysed and assayed for luminescence 48 h after transfection by using commercially available reagents (Luciferase Reporter Gene Assay; Roche). The values recorded by the luminometer were normalized to the total protein concentration in the cell lysates, as determined by using the microBC assay (Interchim). Experiments were repeated at least twice with three replicates per sample for each experiment.
Quantitative PCR (qPCR) and RT-PCR of luc and mRNA. Primers designed within luc to quantify DNA and mRNA levels in transfected cells gave rise to an amplification product corresponding to nt 705-835 on the pSP-Luc + plasmid (Promega; GenBank accession no. U47122). qPCR was performed by using the QuantiTect SYBR green PCR kit (Qiagen). Luciferase mRNA was quantified by using the same primers and the QuantiTect SYBR green RT-PCR kit (Qiagen), as described by Lecollinet et al. (2006) . Housekeeping genes were used to normalize the data [b-globin for PCR and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) for RT-PCR]. Experiments were repeated at least twice with three replicates per sample for each experiment.
Statistical analysis. Data were compared for statistical differences using Student's t-test. Levels of significance were set at P,0.05.
RESULTS

Constructing a map of CAV-2 late transcripts
To analyse the late transcriptional unit of CAV-2, cDNA libraries were constructed at different time points in the infectious cycle. Each library was screened with 59-and 39-RACE PCR using specific primers for all the expected late adenoviral genes (Supplementary Table S1 ), enabling identification and localization of the major late CAV-2 transcripts. The amplification products were cloned and sequenced. The 59 splice sites, ORFs and polyA sites were analysed and the predicted CAV-2 genes are listed in Table  1 . All of the expected major late transcripts were detected in the libraries from 12, 16 and 24 h post-infection. Only the transcript encoding the precursor of 52/55k was detected at early stages of infection, as has been reported for hAds.
Identification of polyA sites enabled us to group the different late transcripts into six families, L1-L6. The general organization of the CAV-2 late unit appeared to be similar to that of other members of Mastadenovirus, as it starts with p52/55k and ends with the fiber transcript. Nevertheless, the mRNA distribution of the families diverged substantially between CAV-2 and hAd type 2 (Fig. 1) .
Analysis of the CAV-2 late genes
Following sequence alignment of the CAV-2 and hAd2 late proteins, sequence similarity was determined (Table 1) . Most of the late proteins analysed, i.e. canine p52/55k, pIIIa, III, pX, pVI and 100k, exhibited a sequence identity of about 50 %. Hexon, protease and pVIII were the most conserved proteins (about 70 % identity), with hexon sequences diverging in two domains comprising aa 130-325 and aa 423-477. The proteins pVII and V displayed 30 % identity: pVII lacked the last 150 aa of its hAd2 counterpart, whereas V contained an extra sequence of about 130 aa beginning at position 220. CAV 33k and fiber proteins were less related to their human counterparts (about 20 % identity). 
Functional organization of CAV-2 MLTU
Identification of CAV-2 leader sequences
Comparison of the 59 untranslated leader sequences from the late CAV-2 mRNAs revealed the same 224 bp region that corresponded to three spatially separated sequences in the CAV-2 genome; this was presumed to be the TPL sequence. The first CAV-2 leader exon was 59 bp, which was longer than the first leader exon of hAd2 (41 bp). The next two leader exons were found to be similar in size to the second and third leader exons of hAd2; these were 72 and 93 bp compared with 72 and 90 bp, respectively. The TPL sequence of CAV-2 was analysed by using the splice site prediction tool NNSPLICE 0.9 (Reese et al., 1997) . This analysis confirmed the organization that was observed for CAV-2 TPL (Fig. 2) . The hAd2 TPL of p52/55k mRNA has been shown to be different in early and late stages of infection: a fourth exon between the first and the second leader exons was found and designated the 'i-leader' (Falvey & Ziff, 1983; Lucher et al., 1986) . Even though p52/ 55k mRNA was found very early in the replication cycle, as described for hAd2, we did not find any difference in the 59 non-coding region of the mRNA.
Location of MLP on the CAV-2 genome
Late adenoviral genes are expressed from a single late transcriptional unit controlled by a strong promoter, the MLP. On the basis of sequence similarity among human and non-human adenoviruses, we have tentatively identified the MLP of CAV-2 (Fig. 3) . Curiously, a CAV-2 TATA-like sequence, located at nt 5458-5464, did not conform to the consensus sequence 59-TATAWADR-39, as it presented a C at the first position. An inverted CCAAT box, as well as downstream elements DE1 and DE2b/a, were also identified. The latter are recognized by virally encoded trans-acting factors, DEF-A and DEF-B, involved in regulating MLP activity (Ali et al., 2007; Lutz & Kedinger, 1996; Ostapchuk et al., 2006; Tribouley et al., 1994) . Upon analysis of the CAV-2 TPL sequence, it was possible to identify a putative transcription start site, AGTTGG (position 5488), 24 bp downstream from the TATA-like box, with a consensus sequence 59-YYNWYY-39 (Javahery et al., 1994) .
CAV-2 MLP enables gene expression and responds to infection
To determine whether the putative MLP of CAV-2 was functional, we constructed plasmids in which the expression of the reporter luciferase gene was placed under the control of the predicted CAV-2 MLP sequence (see Fig. 4a and b). The pMLP-L-Luc bears a 1390 bp fragment of the CAV-2 sequence from the reverse CCAAT box to the TPL, with the natural intron inserted between leaders 1 and 2. To study the minimal promoter sequence of CAV-2 MLP, a second plasmid, pMLP-S-luc, was constructed in which luciferase transcription was placed under the control of a 245 bp fragment comprising the sequence located between the inverted CCAAT box and the CATA box.
These two plasmids were used to transfect DK cells and luciferase activity was assayed. The two MLP constructs enabled a limited, albeit detectable, level of transgene expression (Fig. 4c) , confirming the activity of the cloned promoter sequence. In a second experiment, transfected cells were concomitantly infected with CAV-2, whereupon luciferase expression from pMLP-L-luc was significantly increased by 20-fold (P50.009), confirming viral transactivation of MLP during the replication cycle. CAV-2 infection also transactivated reporter gene expression by The inverted CCAAT and CATA boxes are represented by two ovals, which together form the minimal promoter sequence of the CAV-2 MLP, termed MLP S. MLP S was directly cloned into the BglII and PstI restriction sites of pCMV-luc (see Fig. 5a ). The long form of MLP (MLP L) was constructed by PCR amplification from the CCAAT box to the second TPL exon on the CAV-2 genome and by cloning this product into the BglII and NheI restriction sites of L23 (see Fig. 5a ). pMLP-S-luc, but to a significantly lesser extent (P50.018) than for the longer form of CAV-2 MLP.
Functional importance of the TPL sequence
To gain insight into the role of the CAV-2 leader sequence present in the 59 non-translated region of mRNA in the translation of late viral proteins, we designed plasmids in which luc was preceded by the whole (L123) or portions of the (L12, L23, L3) TPL sequence (Fig. 5a ). These cassettes were subcloned in pCI under the control of the immediateearly CMV promoter and all of the resulting plasmids were introduced into DK cells by transfection. The efficiency of transfection was estimated by quantifying luc DNA by qPCR on total DNA extracted from transfected cells. No differences were observed between the constructs. Luciferase activity was assayed by standard bioluminescence assay and normalized to the total protein concentration (Fig. 5b ). The construct with the entire TPL sequence upstream of luc (construct L123) gave rise to higher luciferase activity (approx. fourfold; P50.017) in transfected cells than the construct without the TPL sequence (pCMV-luc, construction L0). Increased activity was not observed with the other constructs harbouring truncated TPL sequences.
To determine whether this increase in luciferase activity arose from a greater amount of reporter transcript, luciferase mRNA was quantified by RT-PCR on total RNA extracted from cells transfected with L0 or L123 constructs (Fig. 5c ). The quantity of luc mRNA was actually lower in cells transfected with the construct harbouring intact TPL.
DISCUSSION
Molecular characterization of the CAV-2 MLTU was undertaken to enable accurate modification of the CAV-2 genome. All of the late transcripts of CAV-2 were identified and assigned to six families sharing the same polyA site. The late mRNA families of CAV-2 and hAd2 were then compared. Although some unique features of CAV-2 were observed, the general organization and, in particular, the arrangement of the ORFs within the MLTU was conserved between CAV-2 and hAd2. We were also able to identify, clone and functionally analyse the CAV-2 MLP and leader sequences. As in the MLP of hAds, the CAV-2 MLP was found to be a strong promoter that is upregulated during infection and whose activity markedly depends on sequences of the CAV-2 genome located within the intron between the first two TPL exons. Finally, the CAV-2 TPL sequence improved foreign gene expression without concomitant CAV-2 infection and its influence on gene expression was exerted post-transcriptionally.
Following infection of DK cells with CAV-2, cDNA libraries were prepared by RACE PCR, allowing identification of all of the CAV-2 late transcripts corresponding to those described for hAd2. However, the RACE method for transcription mapping only permitted analysis of wellrepresented mRNAs, and it remains possible that rare transcripts escaped detection. For example, the 33k transcript was expected to be found in the early stage of infection, as its encoded protein is thought to be implicated in MLP transactivation (Ali et al., 2007) . We confirmed the predicted location of the ORF for all transcripts analysed, except the pIIIa coding sequence. The splice acceptor site that we identified for the pIIIa transcript was different from that which had been deduced from sequence analysis and deposited in GenBank (Davison et al., 2003) . Thus while the pIIIa ORF was thought to begin at the ATG located at nt 10853 (GenBank accession no. U77082), the authentic acceptor site is followed closely by another in frame ATG (nt 10898), which is likely to be the start codon.
Amino acid sequence alignments of CAV-2 late proteins with their counterparts in hAd2 revealed that some viral proteins are more conserved than others. The CAV-2 and hAd2 fiber proteins were very different with respect to amino acid sequence, potentially related to the differences in tropism between hAd and CAV-2 (Soudais et al., 2000) , although they presented some similarity in organization (Rasmussen et al., 1995) and structure (Schoehn et al., 2008) . On the other hand, the CAV-2 hexon sequence is homologous to its hAd2 counterpart. Nevertheless, seven hypervariable domains have been found to contain speciesand serotype-specific epitopes (Crawford-Miksza & Schnurr, 1996) , some of which are recognized by adenovirus-neutralizing antibodies (Pichla-Gollon et al., 2007) . These domains have reduced homology, as seen by alignment of CAV-2 and hAd2 hexon sequences. The functional domains of the structural protein VI have also been subjected to in-depth study. Sequence alignment of pVI of CAV-2 and hAd2 revealed some conserved domains, especially the nuclear localisation signal sites and the domains that interact with the viral protease (Matthews & Russell, 1995) and hexon protein (Honkavuori et al., 2004; Matthews & Russell, 1994 Wodrich et al., 2003) . In fact, hexon and pVI exhibit the highest sequence similarity between species, probably owing to constraints related to conservation of the interaction domains. The Manhattan strain was used in this study and alignments of late protein sequences with strain Toronto, the type strain for CAV-2, reveal minor differences. A total of six non-synonymous substitutions were found in pIIIa, III, hexon, 100k, 33k and fiber (data not shown). The functional significance of this amino acid polymorphism has not been analysed in relation to the difference in virulence between the two CAV-2 strains.
We also identified and functionally characterized the CAV-2 MLP. The MLP sequences of CAVs were very similar to those of hAd2. The alignment between CAV-2 and hAd2 MLP sequences was more similar within regions corresponding to the typical promoter elements (CCAAT and TATA boxes, trans-acting domains), especially in the viral binding domains DE1 and DE2. On the other hand, regions of the hAd2 MLP known to interact with human cellular factors MAZ and SP1 (Parks & Shenk, 1997) were not shared by CAV. CAV-2 displayed a CATA box instead of a canonical TATA sequence. A non-consensus TATA box is present in many cellular or viral RNA polymerase II promoters, including that of HIV-1 (van Opijnen et al., 2004) . Furthermore, the sequence just following the TATA box of the MLP is markedly AT-rich, whereas the region surrounding TATA boxes is usually GC-rich (Brunet et al., 1987) . This GC-rich region has been described for hAd and it corresponds to binding motifs for cellular transcriptional factors (MAZ, MAZ/SP1) (Parks & Shenk, 1997) ; it is a conserved feature among different hAd and even other non-human adenoviruses (murine, porcine or bovine adenoviruses). The lack of a GC-rich region in the MLP of CAV may reflect divergence in the host, with the CAV MLP being selected by the conditions in canine cells. Expression from the CAV-2 MLP was upregulated during the infectious cycle and full activation of the MLP required elements downstream of the viral promoter, possibly the viral regulation elements DE1 and DE2b/a located within the first intron between the first two TPL exons.
For all of the CAV-2 late mRNAs, a non-coding region corresponding to three exons has been identified. This organization is strikingly similar to the TPL sequence described for human (Chow et al., 1977; Logan & Shenk, 1984) and other non-human adenoviruses such as bovine adenovirus type 3 (Reddy et al., 1998) and chicken embryo lethal organ virus (Payet et al., 1998) . During adenoviral infection, the host cell functions are hijacked in favour of viral replication. In particular, a shut down in translation of cell-derived mRNA is observed in infected cells, which could be related to diminution of cellular mRNA export from nucleus to cytoplasm (Beltz & Flint, 1979) . Moreover, it has been shown that the TPL sequence of species C hAds can increase the efficiency of mRNA export (Huang & Flint, 1998) and is responsible for a cap-independent translation initiation (Xi et al., 2005) . We found that the presence of the CAV-2 TPL sequence upstream of a foreign gene (luc) led to better protein production and that this function seemed to require the entire sequence of CAV-2 TPL. We also observed that the pool of luc mRNA was not increased in the presence of the TPL sequence, indicating that the CAV-2 TPL acts at a post-transcriptional level. In fact, the amount of luc mRNA was even lower in the presence of TPL, possibly related to a reduction in transcription efficiency or mRNA stability. Although its role in supporting transgene expression is not well-defined, the TPL is conventionally introduced into expression cassettes comprising adenoviral late genes (Alonso-Caplen et al., 1988; Berkner, 1988; Moore & Shenk, 1988) . We can confirm that the CAV TPL has potential for improving late viral gene expression, especially when under the control of the CAV-2 MLP.
These results provide a precise and functional map of the CAV-2 late transcriptional unit, including the promoter sequence, leader sequences and ORFs. This study could lay the groundwork for the design of new vectors, in order to improve efficiency and biosecurity of CAV-2 vectors for vaccination or gene therapy purposes.
